StreetInsider.com News Articles

JPMorgan Starts Praxis Precision Medicines Inc. (PRAX) at Overweight

Thu, 15 Oct 2026 16:21:28 -0400

JPMorgan initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Overweight rating and a price target of $700.00.

For an analyst ratings summary and ratings history on Praxis Precision Medicines Inc. click here. For more ratings news on Praxis Precision Medicines Inc. click here.

Shares of Praxis Precision Medicines Inc. closed at $239.02 yesterday.

JPMorgan Starts Praxis Precision Medicines Inc. (PRAX) at Overweight

Thu, 15 Oct 2026 16:21:28 -0400

JPMorgan initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Overweight rating and a price target of $700.00.

For an analyst ratings summary and ratings history on Praxis Precision Medicines Inc. click here. For more ratings news on Praxis Precision Medicines Inc. click here.

Shares of Praxis Precision Medicines Inc. closed at $239.02 yesterday.

UBS Reiterates Neutral Rating on Praxis Precision Medicines Inc. (PRAX)

Wed, 14 Oct 2026 16:45:35 -0400

UBS reiterated a Neutral rating and $706.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)

For an analyst ratings summary and ratings history on Praxis Precision Medicines Inc. click here. For more ratings news on Praxis Precision Medicines Inc. click here.

Shares of Praxis Precision Medicines Inc. closed at $243.34 yesterday.

UBS Reiterates Neutral Rating on Praxis Precision Medicines Inc. (PRAX)

Wed, 14 Oct 2026 16:45:35 -0400

UBS reiterated a Neutral rating and $706.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)

For an analyst ratings summary and ratings history on Praxis Precision Medicines Inc. click here. For more ratings news on Praxis Precision Medicines Inc. click here.

Shares of Praxis Precision Medicines Inc. closed at $243.34 yesterday.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

Thu, 24 Sep 2026 06:44:02 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $1,201.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).

The analyst commented: "As part of our “Biopharma Deep Dive” call series, we recently hosted Marcio Souza, President and Chief Executive Officer of Praxis Precision Medicines. During the call, we discussed relutrigine’s broad potential across developmental and epileptic encephalopathies, the path forward for vormatrigine following POWER1, and ulixacaltamide’s pricing and launch strategy. Ulixacaltamide has remained the focus for investors, but we had the opportunity to discuss several other Praxis programs which underpin our thesis in the name and have kept us

Praxis Precision Medicines Inc. (PRAX) PT Raised to $575 at Goldman Sachs

Fri, 21 Aug 2026 06:29:03 -0400

Goldman Sachs analyst Kevin Strang raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $575.00 (from $470.00) while maintaining a Buy rating.

Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James

Mon, 17 Aug 2026 06:15:52 -0400

Raymond James analyst Tiago Fauth raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $945.00 (from $765.00) while maintaining a Strong Buy rating.

The analyst comments "The next 6-12 months for Praxis represent one of the most compelling setups in SMID biotech. We think of it as a three-course dinner at the finest restaurant in town: relu’s Phase 3 EMERALD readout is the appetizer; ulixa’s PDUFA is the main course; ulixa’s launch in essential tremor is dessert. As appetizers often are, EMERALD is overlooked. We think that is primarily for two reasons: (1) investors understand the therapeutic hypothesis

Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James

Mon, 17 Aug 2026 06:15:52 -0400

Raymond James analyst Tiago Fauth raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $945.00 (from $765.00) while maintaining a Strong Buy rating.

Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26928803.html

Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 14 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26928803.html

Praxis Precision Medicines Inc. (PRAX) PT Raised to $362 at Wells Fargo

Fri, 07 Aug 2026 08:20:33 -0400

Wells Fargo analyst Ben Burnett raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $362.00 (from $323.00) while maintaining a Equal Weight rating.

Praxis Precision Medicines Inc. (PRAX) PT Raised to $462 at RBC Capital

Fri, 07 Aug 2026 07:30:13 -0400

RBC Capital analyst Leonid Timashev raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $462.00 (from $449.00) while maintaining a Outperform rating.

Praxis Precision Medicines Inc. (PRAX) PT Raised to $514 at Baird

Thu, 06 Aug 2026 15:50:36 -0400

Baird analyst Brian Skorney raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $514.00 (from $400.00) while maintaining a Outperform rating.

Form 10-Q Praxis Precision Medicin For: Jun 30

Thu, 06 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26879810.html

Form 10-Q Praxis Precision Medicin For: Jun 30

Thu, 06 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26879810.html

Form 8-K Praxis Precision Medicin For: Aug 06

Thu, 06 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26879790.html

Form 8-K Praxis Precision Medicin For: Aug 06

Thu, 06 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26879790.html

Praxis Precision Medicines (PRAX) Tops Q2 EPS by 367c

Thu, 06 Aug 2026 08:20:40 -0400

Praxis Precision Medicines (NASDAQ: PRAX) reported Q2 EPS of $0.00, $3.67 better than the analyst estimate of ($3.67).

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027

Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026

FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations

Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and